Compare Natera Inc. Common Stock (NTRA) vs Occidental Petroleum Corporation (OXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Occidental Petroleum Corporation — how do they compare? Natera Inc. Common Stock trades at $394.16 (market cap $57.03B), while Occidental Petroleum Corporation trades at $61.4 (market cap $61.63B). The key difference: Natera Inc. Common Stock and Occidental Petroleum Corporation are close in size by market cap, and Occidental Petroleum Corporation pays a 1.82% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Occidental Petroleum Corporation for 92 Days on average.
| NTRA | OXY | |
|---|---|---|
Market Cap | $57.03B | $61.63B |
Volume | 1,131,157 | 9,180,422 |
Sector | Health | Energy |
52-Week High | $425.64 | $66.24 |
52-Week Low | $179.42 | $38.92 |
Typical Hold Time | 0 Days | 92 Days |
Enterprise Value | $56.18B | $80.39B |
Dividend Yield | — | 1.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Occidental Petroleum (OXY) trades at $61.41, up 0.46% with strong technical momentum and bullish moving average signals. The company demonstrates robust profitability with 30.32% net income margin and 21.46% ROE, though revenue has declined from $36.6B in 2022 to $21.6B in 2025. Recent earnings beats and a $71.40 consensus price target suggest upside potential, supported by Goldman Sachs' October 1 upgrade citing cash flow targets and debt reduction plans.
OXY presents a compelling value opportunity with attractive valuation multiples (P/E 18.19, EV/EBITDA 5.66) and strong analyst support (52% buy rating). Key risks include oil price volatility and declining revenue trends, while catalysts include upcoming Q3 earnings and continued operational efficiency improvements. The stock's technical strength and fundamental value create favorable risk-reward dynamics for energy sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →
